BOSTON, March 30, 2026
Praxis Precision Medicines has achieved a major regulatory milestone as the U.S. Food and Drug Administration accepted its New Drug Application (NDA) for relutrigine and granted Priority Review for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)—rare, severe neurological disorders with no currently approved targeted therapies. The agency has set a PDUFA target action date of September 27, 2026, signaling an accelerated pathway that could bring this first-in-class precision therapy to patients sooner
Regulatory Milestone Signals Accelerated Pathway
In a significant step toward commercialization, Praxis announced that the FDA’s acceptance of its NDA marks the company’s first regulatory submission to reach this stage, highlighting its transition into a commercial-stage neuroscience company. The Priority Review designation underscores the urgent unmet medical need in DEEs, where current treatment options are limited and largely symptomatic rather than disease-modifying. If approved, relutrigine could become the first targeted and disease-modifying therapy specifically for SCN2A and SCN8A DEEs, offering new hope for affected children and families facing these life-threatening conditions.
The regulatory recognition is further strengthened by relutrigine’s Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation, reflecting strong clinical potential and the therapy’s importance in addressing rare pediatric neurological disorders. Additionally, approval could make the drug eligible for a Pediatric Review Voucher, adding strategic and commercial value to the program.
Clinical Evidence Demonstrates Strong Efficacy Potential
Advertisement
The NDA submission is supported by compelling data from the EMBOLD Phase 2 study, which was stopped early due to positive efficacy outcomes following a successful interim analysis. The study demonstrated robust improvements in motor seizures, including cases of sustained seizure freedom in heavily pre-treated patients—an outcome rarely observed in this patient population.
Relutrigine operates as a preferential inhibitor of persistent sodium current, targeting a key driver of neuronal hyperexcitability associated with seizures in DEEs. Its precision sodium channel modulation mechanism allows for selective targeting of disease-state neuronal activity, potentially offering improved efficacy with a favorable safety profile. Preclinical and early clinical studies have shown dose-dependent seizure control, including complete seizure suppression in animal models, reinforcing confidence in its therapeutic potential.
Moreover, the drug has demonstrated good tolerability across multiple Phase 1 trials, along with biomarker changes consistent with its mechanism of action, positioning it as a promising candidate in the evolving landscape of precision neuroscience therapies.
Pipeline Expansion and Future Outlook
Beyond the current NDA, relutrigine is also being evaluated in broader DEE populations through the EMERALD clinical trial, expected to be completed by the end of 2026. This study aims to expand the therapeutic scope of relutrigine across additional epilepsy subtypes, potentially increasing its clinical and commercial impact.
Praxis continues to leverage its proprietary small molecule and antisense oligonucleotide platforms to develop innovative treatments for neurological disorders characterized by excitation-inhibition imbalance in the brain. With multiple late-stage candidates across epilepsy and movement disorders, the company is positioning itself as a leader in CNS precision medicine.
The FDA’s decision to grant Priority Review reflects both the strength of clinical data and the critical need for targeted therapies in rare pediatric epilepsies. As the September 2026 decision date approaches, relutrigine stands as a potential breakthrough in the treatment of genetic epilepsies, with the ability to transform care standards and improve long-term outcomes for patients with SCN2A and SCN8A DEEs.
Source: Praxis Precision Medicines press release
